GE HealthCare Q2 2026: Imaging Surge Lifts Earnings

GE HealthCare beat second-quarter profit estimates by nearly 9%, fueled by record orders and robust hospital imaging demand, even as a potential patient care unit divestiture clouds the longer-term outlook.

Lead

What Happened

Revenue for the period reflected organic growth propelled by a surge in capital-equipment orders, with the company reporting 11.1% organic order growth — a company record — and a total backlog of $23.90 billion. Diluted earnings per share climbed 16.5% from the year-ago period, while adjusted EPS advanced 6.6%.

Chief Executive Peter Arduini attributed the results to strong commercial execution and accelerating adoption of newly launched imaging products. "We delivered record orders and backlog in the second quarter, with orders growth across every segment, demonstrating strong commercial execution, including the adoption of new products," Arduini said.

For full-year 2025, the company had reported revenue of $20.6 billion, representing 4.8% growth and 3.5% organic expansion, providing a solid baseline for the current trajectory.

Imaging Drives Momentum

The hospital imaging franchise — GE HealthCare's largest and most strategically significant segment — is at the core of the earnings beat. The company has aggressively refreshed its MRI scanner portfolio over the past twelve months, introducing the Signa Bolt, a high-field 3-tesla wide-bore system, and the Signa Sprint with Freelium technology, a 1.5-tesla platform that uses less than 1% of the helium required by conventional MRI systems — a meaningful operational advantage for hospital procurement teams managing infrastructure costs.

On the computed tomography side, the Photonova Spectra Photon Counting CT, featuring proprietary Deep Silicon technology, is designed to process up to 50 times more data than standard CT scanners, expanding diagnostic precision in oncology and cardiology workflows. Both the MRI scanner and CT product lines are integrated with the Signa One AI-driven workflow platform, which GE HealthCare says reduces technologist training time and improves throughput — addressing one of the sector's most persistent bottlenecks.

Market Reaction and Strategic Context

The 4.89% single-session gain reflected relief that supply-chain headwinds — including memory-chip inflation, elevated freight costs, and tariff pressures — did not materially erode profitability. Management indicated operational mitigations are on track to offset those cost pressures in the second half of the year.

Analyst sentiment remains constructive: 12 of 18 tracked analysts carry Buy ratings on the stock, with the average 12-month price target sitting at $79.33, implying approximately 12% upside from post-earnings levels.

One notable organizational change: Chief Financial Officer Jay Saccaro departed after three years in the role. GE HealthCare is navigating the transition during what management described as a period of strong commercial momentum.

Patient Care Solutions: A Deal in the Making

Beneath the optimistic imaging narrative sits a material strategic question. GE HealthCare has placed its Patient Care Solutions (PCS) unit — which includes patient monitoring systems and premium anesthesia devices and generates approximately $5.3 billion in annual revenue — under formal strategic review. Options under consideration range from continued ownership to an outright divestiture.

Management expects sequential improvement in PCS revenue and margins in the second half of 2026, driven by backlog conversion and increased shipment velocity. FDA clearance for premium anesthesia hardware is also anticipated before year-end, which could enhance the unit's standalone valuation or attractiveness to a buyer.

Separately, the company is reported to be exploring options for its China business, historically the third-largest geographic market with over $2.1 billion in 2024 sales — a review shaped in part by elevated geopolitical and regulatory risk in that market.

Full-Year 2026 Guidance Reaffirmed

GE HealthCare maintained its 2026 outlook unchanged:

• Organic revenue growth: 3.0%–4.0%
• Adjusted EPS: $4.80–$5.00
• Free cash flow: approximately $1.6 billion
• Adjusted EBIT margin: 15.4%–15.7%

The reaffirmation was read positively by the market, given the ongoing macroeconomic uncertainty and tariff environment.

Outlook

GE HealthCare enters the second half of 2026 with a record backlog, a refreshed MRI scanner and imaging portfolio generating strong commercial traction, and a reaffirmed earnings framework. The central variable is the fate of the Patient Care Solutions unit: a divestiture at a meaningful valuation multiple could sharpen the company's focus on the higher-margin imaging and pharmaceutical diagnostics segments, but execution risk around any transaction remains real. The China portfolio review adds another layer of complexity. For now, the hospital imaging engine is performing — and markets are giving management credit for it.